Denosumab for the treatment of bisphosphonate-refractory hypercalcemia

J Clin Oncol. 2012 Oct 10;30(29):e299. doi: 10.1200/JCO.2012.41.7923. Epub 2012 Sep 4.

Authors

Sosipatros A Boikos¹, Hans-Joerg Hammers

Affiliation

¹ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, CRB 186-Oncology, Baltimore, MD 21231, USA. sboikos1@jhmi.edu

PMID: 22949145
DOI: 10.1200/JCO.2012.41.7923

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage*
Bone Neoplasms / complications
Bone Neoplasms / drug therapy
Bone Neoplasms / secondary*
Carcinoma, Renal Cell / complications
Carcinoma, Renal Cell / pathology
Carcinoma, Renal Cell / secondary*
Carcinoma, Renal Cell / surgery
Denosumab
Diphosphonates / administration & dosage*
Disease Progression
Drug Resistance
Fatal Outcome
Humans
Hypercalcemia / drug therapy*
Hypercalcemia / etiology
Hypercalcemia / physiopathology
Imidazoles / administration & dosage*
Kidney Neoplasms / complications
Kidney Neoplasms / pathology*
Kidney Neoplasms / surgery
Male
Middle Aged
Parathyroid Hormone / blood
Risk Assessment
Zoledronic Acid

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Diphosphonates
Imidazoles
Parathyroid Hormone
Denosumab
Zoledronic Acid